liver cancer
Conditions
Interventions
research group:Ultra-stable Lipiodol-Peptuxen-Immune Preparation-Emulsion
Sponsors
Bishan District People's Hospital, Bishan District, Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patient is in good general condition, has no history of other diseases except liver cancer, is not limited to gender, is 18-70 years old, and has a life expectancy of =3 months; 2. Primary cancer confirmed by histology or cytology, or in compliance with the clinical diagnostic criteria (basis of chronic liver disease, typical imaging features, AFP changes) of the "Standards for Diagnosis and Treatment of Primary Liver Cancer" (2022 Edition) promulgated by the National Health Commission patients with hepatocellular carcinoma; 3. BCLC stage B or C, unable to undergo surgical resection 4. There is at least one measurable lesion in the liver; 5. At least one first-level branch of the portal vein is unobstructed; 6. Those whose liver function is Child-A or whose liver function is Child-B can reach Child-A after treatment such as liver protection and nutritional rehydration; 7. Eastern Cooperative Oncology Group status score (ECOG PS) =2; 8. Blood routine, biochemistry, coagulation and other blood indicators are normal; 9. No history of cardiopulmonary disease, normal heart and kidney function, and no cardiotoxic, nephrotoxic or other toxic drugs; 10. Inform the patient in detail about the possible advantages and disadvantages before and after the operation. The patient and his family members voluntarily choose the treatment plan and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have previously received treatment for liver cancer or portal vein tumor thrombus (including surgery, external radiotherapy, molecular targeted drugs, immunotherapy, local ablation, TAI/TACE, etc.) 2. The tumor thrombus extends into the superior mesenteric vein and/or splenic vein; 3. Combined with hepatic vein, segmental inferior vena cava tumor thrombus or extrahepatic metastasis; 4. Combined with diagnosed malignant tumors in other locations; 5. Patients with heart, lung, kidney, brain and other important organ diseases; 6. Contraindications for combined TACE: diffuse liver cancer or tumor volume accounting for 70% or more of the whole liver, refractory large amounts of ascites, high-flow intrahepatic arteriovenous shunt; total bilirubin > 51umol/L and/or albumin < 28g/L, those who fail to improve after symptomatic treatment; combined with active infection, especially inflammation of the bile duct system; female patients who are pregnant or lactating 7. Patients and/or family members do not agree to participate in clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response,OR;disease control,DC;PFS,progression-free survival;downsale rate;surgical resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| liver function;Blood routine; | — |
Countries
China
Contacts
Public ContactTao Rui
Department of Hepatobiliary Surgery, Bishan District People's Hospital, Bishan District, Chongqing
Outcome results
None listed